Loading
CorMedix Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 27 Oct 2025.
CorMedix Inc.: what insiders have been doing
CorMedix Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 32 filings signed by 11 insiders.
On the market, 1 insider bought (1 purchase totalling €237k) while 2 insiders sold (3 sales totalling €761k). On balance, insiders were net sellers of €524k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Biggest ticket of the year: €408k, sold by Lefkowitz Steven W and made public on 10 December 2025.
With 32 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 15 purchases and 4 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 311.7 m USD and net income at 163.1 m USD.
The clock since the last published purchase (27 October 2025) now reads 356 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
93
Thresholds
n/a
Buy Volume
€641,430
15 ops. · all time
Sell Volume
€806,704
4 ops. · all time
Who traded when
BuySaleJanet Dillione2 sales
Myron Kaplan1 buy
Steven W. Lefkowitz1 sale
Since the insiders bought
- -30.3%Entry US$11.14 · Close at T+90 US$7.76
- +43.6%Entry US$3.90 · Close at T+365 US$5.60
- -26.2%Entry US$5.12 · Close at T+365 US$3.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CorMedix Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$15.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 42 of 24,148 companies
92.9
score / 100
Value96
Quality90
FCF yld31%
Earn yld29%
EV/EBITDA4.3x
ROE55%
Gross mgn88%
Net mgn52%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.39
Analyst consensus
6 analystsStrong buy
US$13.00Target US$15.33(+107%)US$19.00
Income statement
RevenueUS$311.7M
Gross profitUS$275.7M88% margin
EBITDAUS$167.3M54% margin
Net incomeUS$163.1M40.5% margin
Valuation
PER (trailing)3.6x
PER (forward)25.6x
P/Book1.2x
Beta1.41
Balance sheet & cash
Market capUS$576M
Total debtUS$148.9M
Free Cash FlowUS$172.8M
Debt / Equity32%
Profitability & ownership
ROE54.9%
ROA24.6%
% insiders7.6%
% institutions57.8%
Last declaration on 18 September 2026
Declarations93 total
48,909 sharesCommon StockSEC:0001213900-26-101594:0
8,424 shares@ US$8.300.011% mcap100.0% of flowCommon StockSEC:0001213900-26-096386:0
8,424 shares@ US$8.300.011% mcap12.5% of flowCommon StockSEC:0001213900-26-096383:0
8,076 shares@ US$8.300.011% mcap14.7% of flowCommon StockSEC:0001213900-26-096385:0
36,006 shares0Common StockSEC:0001213900-26-013407:0
77,156 shares0Common StockSEC:0001213900-26-013406:0
36,006 shares0Common StockSEC:0001213900-26-013408:0
72,820 shares0Common StockSEC:0001213900-26-008482:0
72,820 shares0Common StockSEC:0001213900-26-008480:0
30,453 shares0Common StockSEC:0001213900-26-008472:0
93,010 shares0Common StockSEC:0001213900-26-008479:0
225,900 shares0Common StockSEC:0001213900-26-008478:0
30,453 shares0Common StockSEC:0001213900-26-008477:0
30,453 shares0Common StockSEC:0001213900-26-008476:0
30,453 shares0Common StockSEC:0001213900-26-008475:0
30,453 shares0Common StockSEC:0001213900-26-008474:0
30,453 shares0Common StockSEC:0001213900-26-008473:0
10,000 shares@ US$6.8810.3% of flowCommon StockSEC:0001213900-26-006876:0
5,794 shares@ US$7.159.1% of flowCommon StockSEC:0001213900-26-005426:0
17,417 shares@ US$7.157.1% of flowCommon StockSEC:0001213900-26-005425:0
133,156 shares0Common StockSEC:0001213900-26-004857:0
15,000 shares@ US$5.6312.4% of flowCommon StockSEC:0001213900-26-004470:0
10,895 shares@ US$12.1628.8% of flowCommon StockSEC:0001213900-26-001938:0
11,333 shares@ US$12.1624.4% of flowCommon StockSEC:0001213900-26-001937:0
20,000 shares@ US$4.0357.0% of flowCommon StockSEC:0001213900-26-000712:0
25 of 93 declarations
About CorMedix Inc.
CorMedix Inc. is a US-based biopharmaceutical company listed on the NASDAQ in the United States. Over the past several years, the company has evolved from a narrowly focused developer into a broader commercial specialty-pharma platform centered on acute-care injectable products and hospital-adjacent infectious disease therapies. CorMedix was originally formed under the name Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in 2007. Its corporate footprint is concentrated in New Jersey, with headquarters now associated with Parsippany and additional operational presence in Berkeley Heights. ([stockanalysis.com](https://stockanalysis.com/stocks/crmd/company/?utm_source=openai))
The company’s core commercial story is built around DefenCath, a taurolidine-and-heparin catheter lock solution designed to reduce catheter-related bloodstream infections in hemodialysis patients. DefenCath received FDA approval in November 2023 and was launched in the United States in 2024, first in the inpatient setting and later in the outpatient setting. Management has stated that its contracted dialysis customer base covers a meaningful share of the US outpatient dialysis-center market, which gives CorMedix a real, albeit still specialized, commercial platform rather than a purely development-stage profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm))
Read moreShow less
A major strategic inflection point came in 2025 with the acquisition of Melinta Therapeutics, completed on August 29, 2025. That transaction materially broadened the product set beyond DefenCath, adding a portfolio of anti-infectives and related commercial assets, plus contract and royalty revenue streams. CorMedix now describes itself as a diversified specialty injectables company with eight products in its current portfolio, including DefenCath, six anti-infectives, and a mature branded product. The company’s commercial positioning is centered on hospitals, integrated delivery networks, physician offices, infusion centers, home infusion, and long-term acute-care facilities. ([cormedix.com](https://cormedix.com/wp-content/uploads/2025/09/CorMedix_Corporate-Presentation_9-19-25.pdf))
From a competitive standpoint, CorMedix remains smaller than the major multinational pharmaceutical groups, but it has carved out a niche in high-acuity anti-infective care where clinical differentiation and channel access matter. Its strategic edge lies in combining an approved flagship asset with a broader portfolio that can be sold through overlapping acute-care call points. The company also highlights label-expansion opportunities and pipeline programs, including studies aimed at expanding DefenCath and REZZAYO into larger addressable markets. ([cormedix.com](https://cormedix.com/wp-content/uploads/2025/09/CorMedix_Corporate-Presentation_9-19-25.pdf))
Recent developments underscore the improved scale of the business. In its 2025 annual report, CorMedix reported total revenue of $311.7 million and net income of $163.1 million, driven primarily by product sales of DefenCath and supplemented by the acquired Melinta portfolio. The company also reported that it achieved profitability in 2025 and continued to assess additional growth initiatives, integration benefits, and clinical-expansion opportunities in 2026. For investors, CRMD represents a NASDAQ-listed US healthcare company with a commercial product, a broadened specialty portfolio, and a strategic growth plan still in execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
